PDCD1 and cancer: Immune checkpoint blockade with monoclonal antibodies targeting the programmed death-ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) prolonged patient survival, considering many cancer types [7].